Technology

Haemequine is a natural equine supplement developed to support horses affected by Exercise Induced Pulmonary Haemorrhaging (EIPH), commonly referred to as bleeding.

The incidence of EIPH has long been a major challenge within the equine industry. Over the years, many champion horses have seen their careers shortened due to this condition. Haemequine was formulated to address this ongoing issue through a natural, holistic approach.

The theoretical foundation behind Haemequine is extensive and highly technical. However, its effectiveness is clear—since its introduction in 1995, the product has demonstrated a success rate of over 85% in supporting horses affected by EIPH.

The first documented success with Haemequine occurred in 1995 in Kentucky, USA. Two high-value mares, previously unresponsive to all known bleeding treatments, were placed on Haemequine with owner consent. After approximately seventeen days of supplementation, both horses returned to racing and won without any signs of bleeding. This breakthrough led to widespread adoption among trainers.

The name Haemequine is derived from the medical terms haemoglobin and haematopoietic. The formulation was developed using strict ingredient parameters and exclusively natural components, following a holistic philosophy.

This approach resulted in several key benefits for both horses and industry professionals:

1. The supplement is easily assimilated by the horse’s body
2. There is no risk of toxicity when used as directed
3. It can be safely used on race day without violating prohibited substance regulations
4. Horses using Haemequine can compete internationally without restriction

Field Trial – Part I (May 31, 1995 to October 31, 1995)

Thirty actively racing thoroughbred horses of varying ages and sexes were selected for the initial trial. All horses were under the care of qualified trainers and veterinarians and were classified as extreme bleeders that had failed to respond to modern bleeding medications.

Throughout the trial, the horses remained in full training and received the recommended daily dosage of Haemequine. After a 28-day supplementation period, each horse was trained or raced over five furlongs at maximum speed. All horses were scoped afterward and found to be negative for EIPH.

Field Trial – Part II

A second group of twenty talented thoroughbred horses—known for high expectations but poor race performance—were fed half the recommended daily dosage of Haemequine.

After ten days, trainers observed increased energy, improved appetite, stronger blood counts, and healthier, glossier coats
After twenty-one days, performance levels improved significantly, with over 70% of the horses reaching the winner’s circle
In conclusion, the Equinox Group of Companies appreciates the opportunity to present Haemequine to the equine industry. This natural supplement represents a reliable, proven option for supporting respiratory health, performance, and longevity in equine athletes.